CoChat
Sign Up
Cited by 9Chronic Kidney Disease and DiabetesDiabetes Management and ResearchAcute Kidney Injury Research

The DOI matches its Crossref record; 220 of the 220 references it cites were found in a registry or an index.

Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease

Kugathasan, Luxcia, Aronson, Yarden, Sridhar, Vikas S., Ni, Huajing, Ouimet, Jean-Philippe, Limonte, Christine P., Sarma, Shohinee, Cherney, David Z. I.·2025·Expert Review of Clinical Immunology
DOI 10.1080/1744666x.2025.2537446
Open this paper in CoChat — free account

Abstract

Introduction For decades, the first-line treatment for kidney protection in people with type 1 diabetes (T1D) and chronic kidney disease (CKD) has been limited to intensive glycemic control, renin-angiotensin system blockers and managing modifiable risk factors. Accordingly, risk of CKD progression has remained unacceptably high, emphasizing the need for novel kidney protective therapies in T1D. Areas covered This review summarizes the recent evidence supporting the use of existing treatments used for kidney protection in people with type 2 diabetes (T2D) for potential repurposing for people with T1D. First, we highlight the putative structural and functional changes that actively contribute to CKD progression and highlight key hemodynamic, pro-inflammatory, and kidney injury risk markers in T1D. Next, we discuss emerging nephroprotective therapies targeting these pathophysiological factors, review mechanistic studies that have assessed kidney benefits of these agents in T1D, and highlight ongoing kidney-focused trials in T1D, including SUGARNSALT (NCT06217302), FINE-ONE (NCT05901831) and REMODEL-T1D (NCT05822609). Expert opinion Several medications have become available that could potentially transform CKD care in T1D. It is essential to devise strategies that could address the treatment landscape for kidney protection in T1D by assessing the risk-benefit calculus and expanding the nephrologist's toolkit for minimizing kidney risk in T1D.

Overview

Integrity signals

Registry

Crossref · 10.1080/1744666x.2025.2537446

Cites

220 of 220 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 220 references

Research works printed but not linked: 1

  1. 10.1016/j.jdiacomp.2021.107880 · DOI

Cited by

Sorted by citations

See all 9

Related

Metadata

Authors
Kugathasan, L., Aronson, Y., Sridhar, V. S., Ni, H., Ouimet, J.-P., Limonte, C. P., Sarma, S., & Cherney, D. Z. I.
Affiliations
  • University Health Network (CA)
  • McGill University (CA)
  • University of Washington (US)
  • University of Toronto (CA)
Corresponding author
Cherney, David Z. I.
ORCID
Venue
Expert Review of Clinical Immunology
Publisher
Informa UK Limited
Published
2025-07-24
Volume
21
Issue
8
Pages
1113-1134
ISSN
  • 1744-666X (ISSN-L)
  • 1744-8409
DOI
10.1080/1744666x.2025.2537446
OpenAlex
W4412557969
Cited by
9
References
220
Citations by year
2026: 8 · 2025: 1
FWCI
1.31
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Review of Clinical Immunology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
type 1 diabetes, chronic kidney disease, renal protection, nephroprotective therapy, drug repurposing, type 2 diabetes, chronic kidney disease progression, renin-angiotensin system inhibitors, inflammation, hemodynamics
MeSH terms
Animals, Clinical Trials as Topic, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Humans, Hypoglycemic Agents, Kidney, Disease Progression, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review